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TREATMENT OF XANTHELASMA WITH VITAMIN B12*
R. C. V. ROBINSON, M.D.
One of the more common clinical manifestations of disturbed lipid metabolism
is the formation of yellowish, plaque-like tumors on the eyelids, known as
xanthelasma palpebrarum. Despite the wealth of literature (1, 2, 3, 4) regarding
the pathogenesis and nature of these tumors, treatment, which rests empirically
on dietary measures or surgery, is unsatisfactory.
The discoveries of Ling and Chow (5, 6), who found a definite effect of vitamin
B,2 on carbohydrate and fat metabolism in laboratory animals and noted that
its effect on weight gain was greater when the diet was high in carbohydrates
than when it was high in fat or fat carbohydrate mixtures, indicated that the
drug could be tried in patients with xanthelasma. While the treatment has not
resulted in dramatic cures, there is sufficient relief of objective symptoms to
justify presentation in preliminary form in the hope that further studies may
lead to a satisfactory medical treatment of the disease.
The only criterion for inclusion in the group was the objective finding of
one or more characteristic plaques. In a study of the incidence of xanthelasma
(7), it was noted that the condition is more frequently seen in elderly Jews than
in non-Jews of the same age group. In that study it was also found that the
cholesterol level in xanthelasma patients was not consistently higher than in
patients who were not affected. Furthermore, non-Jews with diabetes mellitus
did not exhibit a tendency toward development of plaques while diabetic Jews
did. The data presented here deal with the therapeutic effect of vitamin B,,.
Thirty-five patients have been treated with the drug administered in doses
ranging from 30 micrograms to one milligram given subcutaneously once weekly
for six to twenty weeks. The results in these patients are outlined in Table I.
Since in no instance was there complete involution of all lesions, critical
evaluation of the therapeutic results by "degrees of improvement" was not
practicable. Because objective improvement was observed in most patients,
it was arbitrarily decided to call the result excellent if one or more smaller
lesions underwent involution to the point where they were no longer clinically
apparent, while a "good" result was obtained when all lesions diminished in size
appreciably. Patients denoted "failures" showed no change.
Patients who received the smaller doses improved more slowly, treatment
being extended over a two to four month period, after which chemical cautery
with liquefied phenol was used to remove the remainder of the lesion.
There was no essential difference in results in those patients receiving 500 or
1000 microgram doses. Improvement was noted usually by the end of the
third week and by the end of six weeks almost all lesions were fiat, although
the superficial changes were still present. Application of liquefied phenol to the
* From the Division of Dermatology, Boggs Medical Service of Baltimore City Hospitals.
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TABLE I
Thirty-five patients with xanthelasma treated once weekly with parenteral
vitamin Bu
Results
No. of Patients Dose, Micrograms ..
Good* Excellentt Failure
10 30 8 0 2
10 500 7 2 1
15 1000 11 3 1
* Definite diminution in size of plaques.
Marked diminution in size of all plaques with complete involution of one or more
smaller lesions.
NOTE: Since most of the diminution in size was a flattening process rather than an
actual reduction in linear dimensions, objective improvement is based on clinical impres-
sion rather than accurate measurement.
TABLE II
Thirty patients with xanthelasma treated with 1.0 my. vitamin B12 given
orally, daily for SO days
No. of Patients
Results
Improved No change
30 5 25
TABLE III
Vitamin B12 blood levels in 13 elderly patients with zanthelasma after oral administration of
a single dose of drug
Total Patients Patients With Rise
Control
1 milligram
3 milligrams
2
8
3
0
5
3
TABLE IV
Effect of vitamin B12 on cholesterol level
Method of Number of Average Control
Administration Patients C olesterol5mg.
Oral* 30 350
Parenteral 35 165
Weeks After B12
One Two Three Four
320 345 360 340
185 140 170 180
* All elderly Jews.
lesions bi-weekly for six to ten treatments sufficed to clear them without obvious
scarring.
No biopsies were done and insufficient time has elapsed to rule out the possi-
bility of recurrence. Further observations are therefore indicated.
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Thirty patients were treated with oral vitamin B12, one milligram being given
daily for thirty days. The results are shown in Table II.
The results in this group of patients were disappointing, since it was hoped
that large doses administered orally would give results comparable to those
obtained with 30 micrograms parenterally.
In an effort to determine a reason for the failure of oral drug, absorption stud-
ies were done on 13 patients. Table III outlines the results.
As was expected, patients given placebo showed no rise in B12 levels. Eight
patients were given a single one milligram dose and blood samples were drawn
at the end of one and a half and three hours. Five showed an increase of 150
micro-micrograms or more. All three of the patients given three milligram doses
had a significant increase in blood level.
The above data leave little doubt that B12 is absorbed from the gastrointestinal
tract of elderly people but give no lead as to the reason for failure of oral medica-
tion to give good results in xanthelasma.
Since cholesterol metabolism has been associated with xanthelasma, a study
was done with both oral and parenteral drug to determine possible effect of B12
on cholesterol levels. These results are outlined in Table IV. There is no real
change in cholesterol levels after administration of B12 orally or parenterally.
SUMMARY AND CONCLUSIONS
Sixty-five patients with xanthelasma have been treated with vitamin B12.
Thirty patients were treated with oral drug with poor results.
Thirty-five patients were treated by parenteral administration of vitamin B12
with beneficial results in thirty-one.
The reason for the improvement is obscure but is apparently not related to
any effect on cholesterol metabolism. Further investigations are indicated.
The author acknowledges with gratitude the help and cooperation of Dr. Bacon F. Chow,
Associate Professor of Biochemistry, School of Hygiene and Public Health, Johns Hopkins
University; and the assistance of Dr. Henry Nagel of the Levindale Home. Dr. K. Okuda
of Dr. Chow's staff did the oral absorption determinations.
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